IntroductionEpstein-Barr virus (EBV) has B-cell growth-transforming ability and is linked to a range of B-cell malignancies. 1,2 Of these, posttransplantation lymphoproliferative disease (PTLD) is pathogenetically the least complex. Thus, PTLD tumors arising early after transplantation, when immunosuppression is greatest, resemble EBV-positive in vitro-transformed lymphoblastoid cell lines (LCLs) in cellular phenotype and in expressing the full range of EBV-latent proteins. 3,4 Here, viral transformation appears to be sufficient for tumor growth, whereas in certain late-onset PTLD lesions, viral gene expression is more restricted and tumor evolution has involved additional cellular genetic changes. [5][6][7] Recent studies have found that most PTLD tumors carry hypermutated immunoglobulin sequences, many of which are atypical of conventional antigenselected memory cells. [8][9][10] Indeed, some tumors lacked surface immunoglobulin and had functionally inactivated immunoglobulin sequences, 8 highlighting parallels with another EBV-associated B-cell malignancy, Hodgkin lymphoma (HL), in which the tumor cells are again surface immunoglobulin negative and often carry similarly "crippled" immunoglobulin genes. 11 These findings suggest that EBV infection can promote the survival of atypical post-germinal center (GC) B cells carrying unfavorable or even inactivating immunoglobulin gene mutations. Such cells, arising as failed products of the somatic hypermutation process that occurs during GC transit, normally die by apoptosis 12 ; however, if rescued by EBV, they might form a pool of cells particularly prone to tumor development. Here we ask whether EBV infection of GC B cells in vitro leads to the outgrowth of LCLs with crippled immunoglobulin genes.
Study design Target cell transformationFresh tonsils were obtained with informed consent from 3 adult patients after tonsillectomy. Mononuclear cells were isolated by Ficoll-Isopaque centrifugation and then T-depleted using CD3 Dynabeads (Dynal Biotech, Bromborough, United Kingdom). The resultant B-cell population was stained for the CD10 marker of GC origin 13 using phycoerythrin (PE)-Cy5-labeled anti-CD10 (BD Pharmingen, Oxford, United Kingdom) monoclonal antibody (mAb) and CD10 ϩ cells collected by fluorescence-activated cell sorter (FACS) on a Mo-Flo sorter (Dako Cytomation, Ely, United Kingdom). In parallel experiments involving different adult donors, naive, and memory B cells were isolated from peripheral blood B cells by FACS sorting of immunoglobulin D ϩ (IgD ϩ )CD27 Ϫ and IgD Ϫ CD27 ϩ subsets, respectively, after staining with FITC-labeled anti-IgD (Caltag, Buckingham, United Kingdom) and RPE (R-phycoerythrin)-labeled anti-CD27 (BD Pharmingen) mAbs. Target B cells were exposed to B95.8 EBV for 1 hour at 37°C and then were seeded at limiting dilutions onto wells containing a human fibroblast feeder layer. Cells were maintained in RPMI 1640 medium supplemented with 2 mM glutamine and 10% vol/vol fetal calf serum (FCS) for 3 to 4 weeks, at which time isolated wel...